PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩180 per share · Prices as of the 2026-10-02 close
Korea Drug, heavily exposed to respiratory-disease demand, has shrunk revenue since 2022 while maintaining double-digit operating margins, but a large net loss in Q2 2026 despite solid operating profit has introduced a new below-the-line variable to watch.
2025 revenue fell to KRW 62.5bn year over year, yet net income attributable to owners rose to KRW 6.5bn, showing an earnings recovery.
Q2 2026 operating profit jumped to KRW 2.66bn quarter over quarter, but owners' net income swung to a loss of KRW 3.44bn, creating a gap between operating and bottom-line results.
Respiratory-system drugs account for the overwhelming share of sales, making results highly sensitive to fluctuations in cold and respiratory patient volume.
The debt-to-equity ratio stands at a low 13.5%, indicating a relatively stable financial structure.
The company turned from a 2023 net loss to consecutive profits in 2024 and 2025, but revenue itself has continued shrinking, from KRW 79.98bn in 2022 to KRW 62.51bn in 2025.
Korea Drug is a small-to-mid-cap KOSDAQ-listed pharmaceutical company that manufactures and sells both prescription and over-the-counter drugs, operating a KGMP-certified plant in Munmak, Gangwon Province that produces solid dosage forms, oral and topical liquids, and health functional foods.
According to the Q1 2026 quarterly report, sales by product category were led by respiratory-system drugs at 65.4%, followed by antipyretic/analgesic/anti-inflammatory drugs at 15.0%, dermatological products at 9.5%, digestive drugs at 7.3%, and antibiotics at 2.4%, with respiratory drugs accounting for the vast majority of revenue.
Its flagship brand is the comprehensive cold medicine 'Haven' series, which includes multiple lineups such as Haven-S, Haven-Q, and Haven Kids, alongside OTC products such as the ampoule-type tonic drink 'Q-up'.
As prescription drug sales form the core of the business, the company focuses marketing efforts on leveraging clinical and market data through specialized channels. Distribution runs through offices in the Seoul metropolitan area and regional locations supplying wholesalers and client accounts.
The company has disclosed that it continues new drug and product research aimed at drug discovery and differentiated generic development, though specific pipeline candidates' clinical stages or commercialization timelines were not confirmed in recent search results.
Competition centers on the broad OTC cold and analgesic drug market against numerous small and mid-sized peers, where market share depends more on brand strength and distribution reach than on exclusive positioning.
Its health functional food production capability also provides a base for revenue diversification beyond pharmaceuticals.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩14.9B | ₩2.2B | 15.0% |
| 2025Q3 | ₩16.5B | ₩2B | 12.0% |
| 2025Q4 | ₩18B | ₩1.9B | 10.5% |
| 2026Q1 | ₩13.3B | ₩1.2B | 8.8% |
| 2026Q2 | ₩17.6B | ₩2.7B | 15.1% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩80B | ₩14.3B | ₩11.8B | 17.9% | 13.9% | 11.6% |
| 2023 | ₩81.4B | ₩18B | -₩4.9B | 22.2% | −6.4% | 16.4% |
| 2024 | ₩73B | ₩9.1B | ₩3B | 12.5% | 3.8% | 13.8% |
| 2025 | ₩62.5B | ₩6.9B | ₩6.5B | 11.1% | 7.8% | 13.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue rose slightly from KRW 79.98bn in 2022 to KRW 81.37bn in 2023, then contracted for two consecutive years to KRW 73.00bn in 2024 and KRW 62.51bn in 2025. Operating margin, by contrast, peaked at 22.2% in 2023 before declining to 12.5% in 2024 and 11.1% in 2025.
Net income showed a more dramatic pattern: a KRW 11.81bn profit in 2022 flipped to a KRW 4.92bn net loss in 2023, before recovering to profits of KRW 3.00bn in 2024 and KRW 6.51bn in 2025, expanding for two straight years.
On a quarterly basis, from Q2 2025 (revenue KRW 14.94bn, operating profit KRW 2.24bn) through Q4 2025 (revenue KRW 18.00bn, operating profit KRW 1.89bn), revenue grew while operating profit gradually eased; in Q1 2026, revenue fell sharply to KRW 13.34bn on seasonality, with operating profit shrinking to KRW 1.18bn.
In Q2 2026, however, revenue rebounded to KRW 17.57bn and operating profit reached KRW 2.66bn, the highest of the past five quarters, yet owners' net income flipped to a loss of KRW 3.44bn.
This points to a clear divergence between operating profit and net income, and no specific below-the-line factor was confirmed through search, warranting attention to subsequent disclosures.
Combined owners' net income over the trailing four quarters (Q3 2025 through Q2 2026) came to roughly KRW 1.48bn, suggesting the Q2 2026 net loss significantly weighed on the cumulative figure.
In sum, the company sustained double-digit operating margins through cost efficiency despite structural revenue pressure, but the Q2 2026 net loss stands out as an exceptional variable in that trend.
Media analysis of 2025 annual reports from listed Korean pharmaceutical companies found that combined 2025 revenue across 65 KOSPI and KOSDAQ pharma firms grew 7.6% year over year, while net income rose 43.3%, indicating an industry-wide improvement in profitability metrics.
In that analysis, Korea Drug was classified among 15 listed pharma firms posting double-digit operating and net margins, suggesting that while its revenue scale is modest, its margin management ranks among the sector's stronger performers.
However, the company's core respiratory drug franchise is inherently sensitive to infectious disease cycles and seasonality, and a decline in respiratory patient volume following the pandemic-era surge has been cited as a structural driver of shrinking revenue.
The company itself has attributed sales declines in disclosures to fewer respiratory patients.
Meanwhile, chronic-disease markets such as osteoporosis and musculoskeletal treatments are expected to see moderate growth from population aging, but Korea Drug's current portfolio appears to have limited direct exposure to this segment.
Across the industry, intensifying generic competition, drug pricing pressure, and rebate regulation remain persistent policy variables, with small and mid-sized pharma companies tending toward defensive positioning built on branded OTC products and stable cash flow.
In its quarterly disclosures, the company has stated its plan to gradually expand its business scope by launching new products and securing new revenue sources through ongoing generic development and clinical research.
However, specific clinical stages or launch timelines for new drug candidates were not confirmed in recently available data, meaning that in the near term, recovery in existing product sales is likely to remain the key earnings variable.
Its core respiratory drug sales carry strong seasonality, so quarterly performance will likely continue to vary depending on the severity of cold and respiratory illness seasons in autumn and winter.
Whether the Q2 2026 net loss was a one-off factor or a recurring variable requires confirmation through subsequent quarterly disclosures. On the balance sheet side, the low debt ratio suggests the company has room to continue R&D and new-product investment without added financial strain.
Whether the company's stated goals of maintaining existing product competitiveness and achieving sales recovery translate into an actual revenue rebound will be a key point to watch in coming quarters.
The current share price sits in a range below book value per share, meaning the market appears to be pricing the stock at a discount to net assets.
On the earnings side, a recovery pattern is evident, moving from a 2023 net loss to consecutive profits in 2024 and 2025, but the Q2 2026 net loss has sharply reduced the combined earnings over the trailing four quarters.
As a result, valuation metrics calculated on recent-period earnings tend to appear elevated relative to what a stable annual earnings base would imply.
On dividends, the company maintains a policy of continued cash distributions, though the level appears relatively modest compared with other companies of similar revenue and earnings scale in the sector.
Ultimately, whether the Q2 2026 net loss proves to be a one-off event and whether earnings normalize in coming quarters are likely to be the key variables in assessing valuation going forward.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
After posting a KRW 4.92bn net loss in 2023, the company grew net income for two consecutive years to KRW 3.00bn in 2024 and KRW 6.51bn in 2025. That profit grew even as revenue contracted over the same period suggests meaningful cost structure management.
Operating margin also held in double digits at 11.1% in 2025, placing it among the sector's stronger performers.
The debt ratio stood at a low 13.5% at end-2025, among the lowest in the past four years (which ranged 11.6% to 16.4%), indicating maintained financial stability. This supports the company's ability to continue R&D and new product investment without external funding pressure even amid revenue contraction. Cash flow from operations also came in at a healthy KRW 13.11bn in 2025 relative to net income.
The current share price trades below book value per share. Combined with a low debt ratio and a stable net asset base, this suggests the market currently values the company's assets at a relative discount. Whether that discount narrows going forward will depend on whether earnings normalize.
Revenue has declined for three straight years, from KRW 79.98bn in 2022 to KRW 62.51bn in 2025. The company has attributed this to fewer respiratory patients, suggesting the reversal of pandemic-era demand continues to weigh on results.
Given the heavy reliance on core product lines, revenue recovery could remain limited absent a structural turnaround.
Q2 2026 operating profit reached KRW 2.66bn, the highest in five quarters, yet owners' net income turned to a KRW 3.44bn loss. This suggests a substantial below-the-line item was involved, though the specific cause was not confirmed through search.
Uncertainty in interpreting results could persist until the nature of that loss (one-off or otherwise) is clarified in future disclosures.
While the company discloses ongoing new drug and product research, specific clinical-stage candidates or commercialization timelines were not identified in publicly available materials.
With the bulk of revenue dependent on existing generic respiratory and analgesic products, the company can be seen as lacking clear new growth drivers. This implies limited diversification to offset seasonal earnings volatility.
Respiratory drugs, which make up the vast majority of revenue, are subject to significant quarterly swings tied to cold and respiratory illness prevalence.
As seen in the post-pandemic demand reversal, sales volatility could persist going forward depending on infectious disease cycles, adding uncertainty to earnings forecasting.
As seen in Q2 2026, net income can swing to a large loss even when operating profit is solid, meaning fluctuations in investment valuation gains/losses or other non-operating items could make net income forecasting difficult. The possibility of such items recurring cannot be ruled out, warranting ongoing monitoring of disclosures.
Policy variables such as intensifying generic competition, drug price cuts, and rebate regulation remain persistent risks across the Korean pharmaceutical industry.
Given a revenue structure centered on general-purpose OTC drugs, the potential for market share erosion from weakened brand strength or aggressive competitor marketing cannot be ruled out.
The Q3 2026 quarterly report will show whether the Q2 2026 net loss was a one-off event and whether the revenue and operating profit recovery trend continues.
Given seasonal demand patterns, sales trends for the core respiratory product line should be checked against the severity of the cold/respiratory illness season.
The 2026 annual business report will confirm full-year revenue and operating margin trends as well as the finalized cash dividend policy.
Follow-up disclosures should confirm whether the company's stated new generic development plans translate into actual product approvals and launches.
Korea Drug is a small-to-mid-cap pharmaceutical company heavily dependent on respiratory drugs, having seen revenue contract continuously since 2022, though it recovered earnings strength by turning from a 2023 net loss into consecutive profit growth in 2024 and 2025.
With an 11.1% operating margin and 13.5% debt ratio in 2025, both financial stability and profitability rank favorably within the sector, but Q2 2026 delivered an unusual outcome: operating profit hit a five-quarter high even as net income swung to a large loss, introducing a new variable into how the earnings trend should be read.
Whether this net loss stemmed from a one-off non-operating factor or represents a recurring risk requires confirmation through subsequent disclosures.
Given the revenue structure's heavy reliance on respiratory disease seasonality, quarterly performance is likely to continue varying with the severity of infectious disease seasons.
New drug and product development plans are mentioned in disclosures, but specific progress stages were not confirmed, limiting visibility on medium-to-long-term growth drivers. Investors should monitor revenue recovery, the nature of the net loss, and seasonal demand trends together.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.